Shares shifted sharply lower on July 28, slipping 9.3% to $159.53, as traders rushed to lock in profits from a multi-day rally that carried Centrus Energy from roughly $163 to $176 in a single week. The sell-off spotlights a core tension for shareholders: the company just landed the biggest contract in its history, but near-term earnings aren't keeping pace with the stock's ambitions.
A $900 Million Government Deal That Sparked the Rally — and the Sell-Off
Centrus signed a $900 million fixed-price contract with the U.S. Department of Energy on July 1 to build large-scale production capacity for HALEU — a specialized uranium fuel needed to power a new generation of advanced nuclear reactors.
The agreement requires delivery of one metric ton of HALEU by March 2032, with DOE options that could push the total contract value to roughly $1.07 billion. That deal ignited the recent rally, but the speed of the run invited the profit-taking now visible in the tape.
Earnings Estimates Are Moving the Wrong Way
Even as revenue guidance rose, Wall Street cut its earnings forecasts. The full-year 2026 EPS consensus fell from $3.19 to $2.85 per share.
Q1 net income already dropped 63.2% year-over-year, with diluted EPS sliding to $0.45 from $1.60 a year earlier — primarily because of higher costs tied to expansion. At today's price, the stock trades at roughly 56 times this year's expected earnings, a steep premium that leaves little room for disappointment.
Short Sellers Are Watching Closely
As of early July, Centrus was the most-shorted energy stock, with short interest at 22.28%. That level of bearish positioning means any negative catalyst — an earnings miss, a DOE budget delay — could accelerate selling, while a short squeeze (where bears are forced to buy shares to cover losses) could amplify a rebound.
The Long Game: Big Backlog, Uncertain Path
Centrus is targeting 12 metric tons of annual HALEU capacity alongside a $2.4 billion LEU backlog, with the first new commercial capacity expected online by 2029.
The company has extended its order backlog to 2040, but its pullback on weaker year-on-year EPS and valuation concerns "keeps the biggest near-term risk squarely on expectations resetting." Investors now must decide whether a three-year wait for meaningful HALEU revenue justifies paying a half-century's worth of earnings today.